Pharmacokinetics of high‐dose etoposide
暂无分享,去创建一个
J. Doroshow | S. Forman | Edward M Newman | James H Doroshow | Stephen J Forman | Karl G Blume | K. Blume | E. Newman
[1] R. Strife,et al. Analysis of the anticancer drugs VP 16-213 and VM 26 and their metabolites by high-performance liquid chromatography. , 1980, Journal of chromatography.
[2] B. Issell,et al. Etoposide (VP-16-213). , 1979, Cancer treatment reviews.
[3] A. Wozniak,et al. DNA damage as a basis for 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity. , 1983, Cancer research.
[4] L. Benet,et al. Noncompartmental determination of the steady-state volume of distribution. , 1979, Journal of pharmaceutical sciences.
[5] P. Bunn,et al. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies. , 1979, Cancer treatment reports.
[6] S. Riegelman,et al. Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion. , 1970, Journal of pharmaceutical sciences.
[7] G R Wilkinson,et al. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. , 1984, Cancer research.